BRCA1 and cancer: HR pathway defects, including BRCA1/2 dysfunction, appear to be present in at least 50% of these cancers, and alterations in the Rb cell cycle regulation pathway, including CCNE1 and RB1 dysfunction, are observed in about 30% [79,81].